Reported 5 months ago
The article compares Inovio Pharmaceuticals and Novavax, two biotech companies that have experienced significant stock price rebounds in 2024. Novavax, which has received approval for its COVID-19 vaccine and struck a major deal with Sanofi, is seen as having better prospects due to higher revenue and financial stability. In contrast, Inovio Pharmaceuticals is developing promising products, including a therapy for a rare disease, but its market capitalization is lower and its success depends largely on regulatory progress. Despite both being risky options, Novavax is considered a better bet due to its stronger financial position.
Source: YAHOO